Couverture de S2 Episode 2: How to Optimize Shared Decision-Making in Psoriatic Arthritis

S2 Episode 2: How to Optimize Shared Decision-Making in Psoriatic Arthritis

S2 Episode 2: How to Optimize Shared Decision-Making in Psoriatic Arthritis

Écouter gratuitement

Voir les détails

3 mois pour 0,99 €/mois

Après 3 mois, 9.95 €/mois. Offre soumise à conditions.

À propos de ce contenu audio

Drs Stanley Cohen and Eric Ruderman discuss shared decision making strategies in psoriatic arthritis management.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970782). The topics and discussions are planned, produced, and reviewed independently of the advertiser. This podcast is intended only for US healthcare professionals.

Resources

Medscape Shared Decision Making https://www.medscape.org/shareddecisionmaking

Psoriatic Arthritis https://emedicine.medscape.com/article/2196539-overview

Treatment Strategies in PsA Management: Use of IL-17 Inhibitors https://decisionpoint.medscape.com/rheumatology/viewarticle/950788

Decision Strategies in PsA Management: Role of IL-23 Inhibitors https://decisionpoint.medscape.com/rheumatology/viewarticle/951718

Ixekizumab Prescribing Information https://uspl.lilly.com/taltz/taltz.html#pi

GRAPPA Treatment Recommendations: 2021 Update https://www.jrheum.org/content/early/2022/03/10/jrheum.211331

Apremilast Prescribing Information https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Otezla/otezla_pi_english.pdf

Psoriatic Arthritis Workup https://emedicine.medscape.com/article/2196539-workup#c6

Decision Strategies in PsA Management: Role of JAK Inhibitors https://decisionpoint.medscape.com/rheumatology/viewarticle/951717

Upadacitinib Prescribing Information https://www.rxabbvie.com/pdf/rinvoq_pi.pdf

Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Aucun commentaire pour le moment